Eosinophilic granulomatosis with polyangiitis

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
4 Unique sponsors
5 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
R Respiratory (ATC R) 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune, humanized) 2 substances
Unknown / small molecule 1 substance
Monoclonal antibody 1 substance
Immunosuppressant 1 substance
Phase III: 3 Phase II: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

3 trials
  • AstraZeneca AB Commercial
    BENRALIZUMAB
    2023-510248-19-00 4 countries 2020 n=72
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    DEPEMOKIMAB
    2023-510019-20-00 11 countries 2022 n=80
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    AZATHIOPRINE; MEPOLIZUMAB
    2024-513653-75-00 1 country 2022 n=100
    Ended

Phase II

1 trial
  • Ns Pharma Inc. Commercial
    METHYL-(1-{[6-{[(1S)-1-CYCLOPROPYLETHYL]AMINO}-2-(PYRAZOLO[5,1-B][1,3]THIAZOL-7-YL)-PYRIMIDIN-4-YL]CARBONYL}PIPERIDIN-4-YL)CARBAMATE-MONO(4-METHYLBENZENESULFONATE) MONOHYDRATE
    2023-504245-32-00 4 countries 2024 n=20
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Ns Pharma Inc. Commercial 1 Phase II 1
AstraZeneca AB Commercial 1 Phase III 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase III 0
Assistance Publique Hopitaux De Paris Academic 1 Phase III 0
New trials by year
2020
1
2022
2
2024
1
← All indication landscapes